Skip to nav Skip to content
Roger  Li

Roger Li, MD

4.8 (279)

Specialty: Urology

Program: Genitourinary Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Bladder Cancer, Kidney (Renal Cell) Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer

    Dr. Roger Li is a genitourinary oncologist whose clinical practice focuses on the surgical treatment of bladder, prostate, kidney and penile cancers. He offers a variety of treatment options, including open, laparoscopic, and robotic-assisted procedures, as well as nerve sparing approaches based on the clinical scenario. Prior to joining Moffitt, Dr. Li completed advanced urologic oncology training at the MD Anderson Cancer Center in Houston, Texas. Dr. Li’s research interest includes the genomic characterization of genitourinary malignancies in attempt to tailor therapy specific to the patient, as well as the development of novel immunotherapeutic strategies in treating early stage bladder cancer. Dr. Li’s work has previously been highlighted in several national and international urology meetings. He has authored numerous peer reviewed manuscripts and book chapters on urologic oncology.  In addition, he serves as reviewer for many international urologic journals, including British Journal of Urology International, European Urology Oncology, Journal of Clinical Genitourinary Cancer, and BMC Cancer. A native of California, Dr. Li received his medical degree from the University of California, Irvine, and completed his urologic residency training at Loma Linda University Medical Center. In his spare time, he enjoys spending time with his family, traveling, and watching and playing basketball.

    Education & Training


    • University of Texas, MD Anderson Cancer Center -


    • Loma Linda University Medical Center -

    Medical School:

    • University of California, Irvine School of Medicine - MD
  • Participating Trials

    Clinical Trial 21690
    A Phase 1b, Single Arm Study of CG0070 after Transurethral Resection in Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
    Condition: Genitourinary
    Intervention: CG0070 (); DDM ()
    Status: Open

    Clinical Trial 22349
    Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
    Condition: Genitourinary
    Intervention: JNJ-42756493 (Erdafitinib)
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Mandula JK, Sierra-Mondragon RA, Jimenez RV, Chang D, Mohamed E, Chang S, Vazquez-Martinez JA, Cao Y, Anadon CM, Lee SB, Das S, Rocha-Munguba L, Pham VM, Li R, Tarhini AA, Furqan M, Dalton W, Churchman M, Moran-Segura CM, Nguyen J, Perez B, Kojetin DJ, Obermayer A, Yu X, Chen A, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. Immunity. 2024 May.57(5):1124-1140.e9. Pubmedid: 38636522. Pmcid: PMC11096038.
    • Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer. Target Oncol. 2024 May.19(3):447-458. Pubmedid: 38570422.
    • Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2024 Mar.85(3):283-292. Pubmedid: 37802683.
    • Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol E, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol. 2024 Mar.37(3):100424. Pubmedid: 38219954.
    • von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. BJU Int. 2024 Mar. Pubmedid: 38470089.
    • von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein MW, Lonati C, Crocetto F, Taylor J, Tully KH, Afferi L, Soria F, Del Giudice F, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, Lotan Y, Spiess PE, Black PC, Kiss B, Pradere B, Shariat SF. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. BJU Int. 2024 Mar.133(3):341-350. Pubmedid: 37904652.
    • Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jun.7(3):614-624. Pubmedid: 38184473.
    • Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Jun. Pubmedid: 38837106.
    • Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Jun. Pubmedid: 38844794.
    • Cigliola A, Prakash G, Li R, Oualla K, Shilpa G, Kamat AM, Chahoud J, Necchi A, Spiess PE. Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions. Curr Oncol Rep. 2024 Jun. Pubmedid: 38847974.
    • Davaro F, Davaro E, Li R. Editorial Comment. J Urol. 2024 Feb.211(2):253. Pubmedid: 38193408.
    • Linscott JA, Meeks JJ, Dyrskjøt L, Li R. The Elusive Horizon: Biomarkers in Urothelial Carcinoma. Eur Urol. 2024 Apr.85(4):317-319. Pubmedid: 38278663.
    • Davaro F, Davaro E, Rose K, Murthy P, Naidu S, Camperlengo L, Grass GD, Vosoughi A, Jain RK, Zemp L, Yu A, Poch MA, Spiess PE, Gilbert SM, Sexton WJ, Li R. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):389.e7-389.e13. Pubmedid: 36959058.
    • Chandra M, Li R, Parwani A, Carson WE, Pohar K, Sundi D. Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics. Urol Oncol. 2023 Sep.41(9):390.e1-390.e17. Pubmedid: 37061453.
    • Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J, Ross JS, Spiess PE. Immunotherapy in the Treatment of Localized Genitourinary Cancers. JAMA Oncol. 2023 Oct.9(10):1447-1454. Pubmedid: 37561425.
    • Peak T, Spiess PE, Li R, Grivas P, Necchi A, Pavlick D, Huang RSP, Lin D, Danziger N, Jacob JM, Bratslavsky G, Ross JS. Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry. Oncologist. 2023 Oct.28(10):e910-e920. Pubmedid: 37196060. Pmcid: PMC10546831.
    • Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
    • Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?. BJU Int. 2023 Oct.132(4):384-386. Pubmedid: 37246493.
    • Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 Oct.6(5):531-534. Pubmedid: 37468392.
    • Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
    • Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment. bioRxiv. 2023 Nov. Pubmedid: 38014063. Pmcid: PMC10680839.
    • Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ, Mine JA, Hänggi K, Sprenger KB, Innamarato P, Harro CM, Powers JJ, Johnson J, Fang B, Eysha M, Nan X, Li R, Perez BA, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. Immunity. 2023 Nov.56(11):2570-2583.e6. Pubmedid: 37909039. Pmcid: PMC10703011.
    • Li R. Organ-sparing precision treatment for muscle-invasive bladder cancer. Nat Med. 2023 Nov.29(11):2709-2710. Pubmedid: 37794252.
    • Murthy PB, Naidu S, Davaro F, Spiess PE, Zemp L, Poch M, Jain R, Vosoughi A, Grass GD, Yu A, Sexton WJ, Gilbert SM, Li R. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Curr Oncol. 2023 Mar.30(3):3223-3231. Pubmedid: 36975458. Pmcid: PMC10046994.
    • Abufaraj M, Li R, Meeks J, Shariat SF. Cytoreductive Surgery in Patients with Urothelial Bladder Cancer. Eur Urol Focus. 2023 Mar.9(2):278-279. Pubmedid: 36509654.
    • Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):452. Pubmedid: 37217696.
    • Davaro F, Jain R, Li R. Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know. Eur Urol Focus. 2023 Jul.9(4):579-581. Pubmedid: 37202260.
    • Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):406-419. Pubmedid: 36977797.
    • Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer. BioDrugs. 2023 Jul.37(4):505-520. Pubmedid: 37256534.
    • Fink AKC, DeRenzis AC, Awasthi S, Jahan N, Johnstone PAS, Pow-Sang J, Torres-Roca J, Grass D, Fernandez D, Naghavi A, Tan S, Manley B, Li R, Poch M, Yu A, Little N, Bass E, Ercole CE, Katsoulakis E, Burri R, Smith R, Stanley NB, Vadaparampil ST, Yamoah K. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study. Cancer Med. 2023 Jan.12(2):1869-1877. Pubmedid: 35796421. Pmcid: PMC9883445.
    • Kumar NB, Bahl S, Dhillon J, Poch M, Manley B, Li R, Schell M, Powsang J. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials. Cancers (Basel). 2023 Feb.15(4). Pubmedid: 36831597. Pmcid: PMC9954186.
    • Necchi A, Spiess PE, Costa de Padua T, Li R, Grivas P, Huang RSP, Lin DI, Danziger N, Ross JS, Jacob JM, Sager RA, Basnet A, Li G, Graf RP, Pavlick DC, Bratslavsky G. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. JAMA Netw Open. 2023 Dec.6(12):e2348002. Pubmedid: 38150257. Pmcid: PMC10753400.
    • Ghelani GH, Zerdan MB, Jacob J, Spiess PE, Li R, Necchi A, Grivas P, Kamat A, Danziger N, Lin D, Huang R, Decker B, Sokol ES, Cheng L, Pavlick D, Ross JS, Bratslavsky G, Basnet A. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 Dec.41(12):486.e15-486.e23. Pubmedid: 37821306.
    • Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec.41(35):5437-5447. Pubmedid: 37793077. Pmcid: PMC10713193.
    • Rose KM, Narang G, Rosen G, Labatte C, Dumitrascu C, Campagna J, Yu A, Manley BJ, Spiess PE, Li R, Adibi M, Murray KS, Sexton WJ, Humphreys MR. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2023 Apr.131(4):471-476. Pubmedid: 36285629.
    • Hugar LA, Gilbert SM, Li R. Editorial Comment. J Urol. 2022 Sep.208(3):578. Pubmedid: 35942791.
    • Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
    • Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct.5(5):505-516. Pubmedid: 35718695.
    • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
    • Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol. 2022 Jun.5(3):347-356. Pubmedid: 33935020. Pmcid: PMC8553807.
    • Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022 Jan.55(1):115-128.e9. Pubmedid: 35021053. Pmcid: PMC8852221.
    • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
    • Li R, Gilbert SM. Editorial Comment. J Urol. 2022 Feb.207(2):312-313. Pubmedid: 34994655.
    • Diaz KA, Spiess PE, Necchi A, Li R, Bandini M, García-Perdomo HA. How to get involved in clinical research: helpful tips. Can J Urol. 2022 Feb.29(1):11024-11026. Pubmedid: 35150226.
    • Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 Dec.114(12):1656-1664. Pubmedid: 36053178. Pmcid: PMC9745424.
    • Ortíz Restrepo A, Ross JS, Spiess PE, Necchi A, Li R, García-Perdomo HA. Emerging targets in upper tract urothelial carcinomas: the TERT gene. Can J Urol. 2022 Dec.29(6):11378-11383. Pubmedid: 36495580.
    • Kumar NB, Hogue S, Pow-Sang J, Poch M, Manley BJ, Li R, Dhillon J, Yu A, Byrd DA. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome. Cancers (Basel). 2022 Aug.14(16). Pubmedid: 36010981. Pmcid: PMC9406482.
    • Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 Apr.40(4):164.e1-164.e7. Pubmedid: 34629281. Pmcid: PMC8960322.
    • Li R, Zhang J, Gilbert SM, Conejo-Garcia J, Mulé JJ. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021 Sep.18(9):543-555. Pubmedid: 34183833.
    • Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney C, McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 Sep.206(3):548-557. Pubmedid: 33881933.
    • Miles BA, McMullen CP, Sweeny L, Zenga J, Li R, Divi V, Jackson R, Patel UA, Richmon JD. Practice patterns of virtual surgical planning: Survey of the reconstructive section of the American Head and Neck Society. Am J Otolaryngol. 2021 Sep.43(1):103225. Pubmedid: 34571439.
    • Chin JL, Lavi A, Metcalfe MJ, Siddiqui K, Dewar M, Petros FG, Li R, Nogueras González GM, Wang X, Nair SM, Ward JF, Pisters L. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. J Urol. 2021 Sep.206(3):646-654. Pubmedid: 33908799.
    • Li R. Editorial Comment. J Urol. 2021 Sep.206(3):567. Pubmedid: 34121428.
    • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
    • Li R, Jain RK, Sexton WJ. Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6. Eur Urol. 2021 Oct.80(4):e99. Pubmedid: 34364728.
    • Green E, Li R. Editorial Comment. J Urol. 2021 Oct.206(4):883-884. Pubmedid: 34378970.
    • Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 Nov.128(5):568-574. Pubmedid: 33484074.
    • Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. BJU Int. 2021 Nov.128(5):634-641. Pubmedid: 33783950.
    • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
    • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
    • Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 Mar.31(2):160-169. Pubmedid: 33394766.
    • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
    • Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Reply by Authors. J Urol. 2021 Jun.205(6):1620-1621. Pubmedid: 33734859.
    • Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
    • Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. J Urol. 2021 Jun.205(6):1612-1621. Pubmedid: 33502236.
    • Britt J, Jain R, Li R. Robotic radical nephroureterectomy in a patient with situs inversus totalis. Urol Case Rep. 2021 Jul.37:101688. Pubmedid: 34040986. Pmcid: PMC8141754.
    • Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. 2021 Jul.80(1):1-3. Pubmedid: 32861573. Pmcid: PMC7448869.
    • Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranisinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. 2021 Jul.128(1):65-71. Pubmedid: 33210440.
    • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
    • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
    • Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, Dyrskjøt L, Kamat AM. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021 Dec.4(6):893-903. Pubmedid: 33975782.
    • Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 Aug.35(8):1168-1176. Pubmedid: 33619985.
    • Li R, Duplisea JJ, Petros FG, González GMN, Tu SM, Karam JA, Huynh TT, Ward JF. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Eur Urol Oncol. 2021 Aug.4(4):651-658. Pubmedid: 31412007.
    • Li R, Lerner SP, Kamat AM. The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. Eur Urol. 2021 Apr.79(4):437-439. Pubmedid: 33454163.
    • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
    • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
    • Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. 2020 Oct.38(10):796.e1-796.e6. Pubmedid: 32430255.
    • Bakhshwin A, Berry RS, Cox RM, Li R, Reynolds JP, Rubin BP, McKenney JK. Malignant solitary fibrous tumour of the prostate: four cases emphasising significant histological and immunophenotypical overlap with sarcomatoid carcinoma. Pathology. 2020 Oct.52(6):643-648. Pubmedid: 32758370.
    • Li R, Kamat AM. Predictors of Response to Intravesical Therapy. Urol Clin North Am. 2020 Feb.47(1):23-33. Pubmedid: 31757297.
    • Liem EIML, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Dat. J Urol. 2020 Feb.203(2):283-291. Pubmedid: 31549936.
    • Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol. 2020 Dec.3(1):784. Pubmedid: 33335285. Pmcid: PMC7746703.
    • Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 Apr.38(4):247-254. Pubmedid: 31953001.
    • Peyton CC, Reich RR, Tang D, Alford B, Azizi M, Li R, Sexton WJ, Poch M, Gilbert SM. Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review. J Urol. 2019 Nov.202(5):913-919. Pubmedid: 31219762. Pmcid: PMC7864380.
    • Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 May.2(3):286-293. Pubmedid: 31200843.
    • Shen J, Ruckle D, Li R, Keheila M, Alsyouf M, Schober J, Tryon D, Stokes P, Ruckle HC, Baron P, De Vera M, Baldwin DD. How a Donor Nephrectomy Population Can Help Give Perspective to the Effects of Renal Parenchymal Preservation During Partial Nephrectomy. J Endourol. 2019 May.33(5):417-422. Pubmedid: 30838888.
    • Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Mar.37(12):2691-2698. Pubmedid: 30864005.
    • Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 Jun.37(6):354.e19-354.e26. Pubmedid: 30777393. Pmcid: PMC6511295.
    • Li R, Spiess PE, Gilbert SM, Necchi A. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. 2019 Jul.76(1):4-6. Pubmedid: 30833139.
    • Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF. Detection and Treatment of Primary Prostatic Melanoma. Urology. 2019 Jan.123:16-19. Pubmedid: 30195014.
    • Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 Jan.75(1):8-10. Pubmedid: 30301695.
    • Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, Dinney CP. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2019 Feb.13(2):24-28. Pubmedid: 30138098. Pmcid: PMC6363565.
    • Li R, Spiess PE, Gilbert SM, Necchi A. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Eur Urol. 2019 Aug.76(2):e34. Pubmedid: 31056228.
    • Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. Eur Urol. 2018 Oct.74(4):405-408. Pubmedid: 29685644.
    • Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. Eur Urol. 2018 May.73(5):738-748. Pubmedid: 29055653.
    • Li R, Petros FG, Davis JW. Extended Pelvic Lymph Node Dissection in Bladder Cancer. J Endourol. 2018 May.32(S1):S49-S54. Pubmedid: 29774757.
    • Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun.116:114-119. Pubmedid: 29578041.
    • Li R, Metcalfe M, Kukreja J, Navai N. Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. Bladder Cancer. 2018 Jan.4(1):31-40. Pubmedid: 29430505. Pmcid: PMC5798530.
    • Li R, Baack Kukreja JE, Kamat AM. Secondary Tumors After Urinary Diversion. Urol Clin North Am. 2018 Feb.45(1):91-99. Pubmedid: 29169454.
    • Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 Feb.121(2):244-251. Pubmedid: 28872778. Pmcid: PMC5780258.
    • Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer P D. 2018 Apr.21(1):4-21. Pubmedid: 29230009.
    • Li R, Petros FG, Davis CJ, Ward JF. Characterization of Glomus Tumors of the Kidney. Clin Genitourin Cancer. 2017 Sep. Pubmedid: 28967505.
    • Shen JK, Faaborg D, Rouse G, Kelly I, Li R, Alsyouf M, Myklak K, Distelberg B, Staack A. Applying translabial ultrasound to detect synthetic slings-You can do it too! A comparison of urology trainees to an attending radiologist. Neurourol Urodyn. 2017 Sep.36(7):1763-1769. Pubmedid: 28185316.
    • Li R, Ruckle D, Keheila M, Maldonado J, Lightfoot M, Alsyouf M, Yeo A, Abourbih SR, Olgin G, Arenas JL, Baldwin DD. High-Frequency Dusting Versus Conventional Holmium Laser Lithotripsy for Intrarenal and Ureteral Calculi. J Endourol. 2017 Mar.31(3):272-277. Pubmedid: 27960541.
    • Li R, Sylvester R, Dinney CP, Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer. 2017 Jul.3(3):147-148. Pubmedid: 28824941. Pmcid: PMC5545908.
    • Li R, Amrhein J, Cohen Z, Champagne M, Kamat AM. Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients. Bladder Cancer. 2017 Jan.3(1):65-71. Pubmedid: 28149937. Pmcid: PMC5271425.
    • Khater N, Keheila M, Lightfoot M, Shen J, Abourbih S, Alsyouf M, Li R, Baldwin DD. Predictors of narcotic use after percutaneous nephrolithotomy. Can J Urol. 2017 Feb.24(1):8634-8640. Pubmedid: 28263128.
    • Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 Dec.3(6):577-583. Pubmedid: 28753816. Pmcid: PMC5767145.
    • Abourbih S, Alsyouf M, Yeo A, Martin J, Vassantachart JM, Lee M, Maldonado J, Lightfoot M, Li R, Olgin G, Baldwin DD. Renal Pelvic Pressure in Percutaneous Nephrolithotomy: The Effect of Multiple Tracts. J Endourol. 2017 10.31(10):1079-1083. Pubmedid: 28791874.
    • Li R, Hu B. Recognition and Management of Ectopic Ureterocele During Robotic Assisted Laparoscopic Radical Prostatectomy. Urol Case Rep. 2016 Sep.8:15-17. Pubmedid: 27313987. Pmcid: PMC4906080.
    • Arenas JL, Shen JK, Keheila M, Abourbih SR, Lee A, Stokes PK, Li R, Alsyouf M, Lightfoot MA, Baldwin DD. Kidney, Ureter, and Bladder (KUB): A Novel Grading System for Encrusted Ureteral Stents. Urology. 2016 Nov.97:51-55. Pubmedid: 27421780.
    • Li R, Petros FG, Kukreja JB, Williams SB, Davis JW. Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol. 2016 Dec.57(Suppl 2):S155-S164. Pubmedid: 27995219. Pmcid: PMC5161019.
    • Li R, Choi W, Ferguson Rd JE, Metcalfe MJ, Kamat AM. New discoveries in the molecular landscape of bladder cancer. F1000Res. 2016 Dec.5:2875. Pubmedid: 28105319. Pmcid: PMC5225406.
    • Khater N, Shen J, Arenas J, Keheila M, Alsyouf M, Martin JA, Lightfoot MA, Li R, Olgin G, Smith JC, Baldwin DD. Bench-Top Feasibility Testing of a Novel Percutaneous Renal Access Technique: The Laser Direct Alignment Radiation Reduction Technique (DARRT). J Endourol. 2016 11.30(11):1155-1160. Pubmedid: 27758120.
    • Li R, Ruckle HC, Schlaifer AE, El-Shafei A, Yu C, Jones JS. The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in Prostate Cancer Treatment. Urology. 2015 May.85(5):1137-1142. Pubmedid: 25799176.
    • Vassantachart JM, Lightfoot M, Yeo A, Maldonado J, Li R, Alsyouf M, Martin J, Lee M, Olgin G, Baldwin DD. Laser fiber cleaving techniques: effects on tip morphology and power output. J Endourol. 2015 Jan.29(1):84-89. Pubmedid: 24964275.
    • Li R, Lightfoot M, Alsyouf M, Nicolay L, Baldwin DD, Chamberlin DA. Diagnosis and management of ureteral fibroepithelial polyps in children: a new treatment algorithm. J Pediatr Urol. 2015 Feb.11(1):22.e1-22.e6. Pubmedid: 25218353.
    • Alsyouf M, Smith DL, Olgin G, Heldt JP, Lightfoot M, Li R, Baldwin DD. Comparing stone attenuation in low- and conventional-dose noncontrast computed tomography. J Endourol. 2014 Jun.28(6):704-707. Pubmedid: 24517291.
    • Li R, Ruckle HC, Creech JD, Culpepper DJ, Lightfoot MA, Alsyouf M, Nicolay L, Jellison F, Baldwin DD. A prospective, randomized, controlled trial assessing diazepam to reduce perception and recall of pain during transrectal ultrasonography-guided biopsy of the prostate. J Endourol. 2014 Jul.28(7):881-886. Pubmedid: 24641687.
    • Olgin G, Alsyouf M, Han D, Li R, Lightfoot M, Smith D, Nicolay L, Ruckle H, Baldwin DD. Postoperative cystogram findings predict incontinence following robot-assisted radical prostatectomy. J Endourol. 2014 Dec.28(12):1460-1463. Pubmedid: 25380408.
    • Lightfoot M, Li R, Alsyouf M, Nicolay L, Chamberlin D. Transurethral needle biopsy: a novel technique for pathologic diagnosis of bladder tumors in children. J Pediatr Urol. 2014 Dec.10(6):1280-1282. Pubmedid: 25082712.
    • Lightfoot M, Ng C, Engebretsen S, Wallner C, Huang G, Li R, Alsyouf M, Olgin G, Smith JC, Baldwin DD. Analgesic use and complications following upper pole access for percutaneous nephrolithotomy. J Endourol. 2014 Aug.28(8):909-914. Pubmedid: 24548123.
    • Blair B, Huang G, Arnold D, Li R, Schlaifer A, Anderson K, Engebretsen S, Wallner C, Olgin G, Baldwin DD. Reduced fluoroscopy protocol for percutaneous nephrostolithotomy: feasibility, outcomes and effects on fluoroscopy time. J Urol. 2013 Dec.190(6):2112-2116. Pubmedid: 23764072.
    • Li R, Louie MK, Lee HJ, Osann K, Pick DL, Santos R, McDougall EM, Clayman RV. Prospective randomized trial of three different methods of nephrostomy tract closure after percutaneous nephrolithotripsy. BJU Int. 2011 May.107(10):1660-1665. Pubmedid: 20973909.
    • Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA, Hu S. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci. 2010 Sep.11(9):3106-3121. Pubmedid: 20957082. Pmcid: PMC2956083.
    • Kolla SB, Gamboa AJ, Li R, Santos RT, Gan JM, Shell C, Andrade L, Louie MK, Clayman RV, McDougall EM. Impact of a laparoscopic renal surgery mini-fellowship program on postgraduate urologist practice patterns at 3-year followup. J Urol. 2010 Nov.184(5):2089-2093. Pubmedid: 20850830.
    • Liss MA, Osann K, Canvasser N, Chu W, Chang A, Gan J, Li R, Santos R, Skarecky D, Finley DS, Ahlering TE. Continence definition after radical prostatectomy using urinary quality of life: evaluation of patient reported validated questionnaires. J Urol. 2010 Apr.183(4):1464-1468. Pubmedid: 20171689.
  • Grants

    Title: Identifying Risk Factors for Progression and Recurrence in NMIBC Using Artificial Intelligence
    Sponsor: Valar Labs
    PI: Li, R.
    Title: Identifying Histopathologic and Molecular Characteristics that Predicts Recurrence in Low Grade Non-Muscle Invasive Bladder Cancer
    Sponsor: The Hope Fdtn
    PI: Li, R.
    Title: The Role of ctDNA in the Management of Urothelial Cancer
    Sponsor: Predicine, Inc
    PI: Li, R.
    Title: Decoding the Resistance Mechanisms to Oncolytic Virotherapy in Muscle Invasive Bladder Cancer
    Sponsor: US Army
    PI: Li, R.
    Title: A Phase 1 Study of CG0070 in Intermediate Risk Non-Muscle Invasive Bladder Cancer
    Sponsor: BCAN (Bladder Cancer Advocacy Network)
    PI: Li, R.
  • Patient Comments

    Overall Satisfaction


    279 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor